The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
What is the economic value created by adding rituximab to chemotherapy in the United States from 1998 to 2013?
Mark D. Danese
Consultant or Advisory Role - Roche/Genentech
Research Funding - Roche/Genentech
Carolina M. Reyes
Employment or Leadership Position - Roche/Genentech
Stock Ownership - Roche/Genentech
Michelle L. Gleeson
Research Funding - Roche/Genentech
Marc Halperin
Research Funding - Roche/Genentech
Sandra L. Skettino
Employment or Leadership Position - Roche/Genentech
Stock Ownership - Roche/Genentech
Joseph Mikhael
Research Funding - Celgene; Novartis; Onyx; Sanofi